AU623336B2 - Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives - Google Patents

Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives Download PDF

Info

Publication number
AU623336B2
AU623336B2 AU11766/88A AU1176688A AU623336B2 AU 623336 B2 AU623336 B2 AU 623336B2 AU 11766/88 A AU11766/88 A AU 11766/88A AU 1176688 A AU1176688 A AU 1176688A AU 623336 B2 AU623336 B2 AU 623336B2
Authority
AU
Australia
Prior art keywords
treatment
pge1
prostaglandin
derivatives
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU11766/88A
Other languages
English (en)
Other versions
AU1176688A (en
Inventor
Herbert Bippi
Jurgen C. Frolich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of AU1176688A publication Critical patent/AU1176688A/en
Application granted granted Critical
Publication of AU623336B2 publication Critical patent/AU623336B2/en
Assigned to RATIOPHARM GMBH reassignment RATIOPHARM GMBH Alteration of Name(s) in Register under S187 Assignors: BIPPI, HERBERT, FROLICH, JURGEN C.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU11766/88A 1987-02-16 1988-02-16 Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives Ceased AU623336B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3704825 1987-02-16
DE19873704825 DE3704825A1 (de) 1987-02-16 1987-02-16 Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU15184/92A Division AU649130B2 (en) 1987-02-16 1992-04-24 Pharmaceutical compositions for transcutaneous administration

Publications (2)

Publication Number Publication Date
AU1176688A AU1176688A (en) 1988-08-18
AU623336B2 true AU623336B2 (en) 1992-05-14

Family

ID=6321070

Family Applications (2)

Application Number Title Priority Date Filing Date
AU11766/88A Ceased AU623336B2 (en) 1987-02-16 1988-02-16 Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives
AU15184/92A Ceased AU649130B2 (en) 1987-02-16 1992-04-24 Pharmaceutical compositions for transcutaneous administration

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU15184/92A Ceased AU649130B2 (en) 1987-02-16 1992-04-24 Pharmaceutical compositions for transcutaneous administration

Country Status (11)

Country Link
EP (1) EP0292643B1 (enExample)
JP (1) JPS63246331A (enExample)
AT (1) ATE80616T1 (enExample)
AU (2) AU623336B2 (enExample)
CA (1) CA1327359C (enExample)
DE (2) DE3704825A1 (enExample)
DK (1) DK173552B1 (enExample)
ES (1) ES2043696T3 (enExample)
GR (1) GR3005743T3 (enExample)
HU (1) HU199687B (enExample)
ZA (1) ZA881053B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2939569A (en) * 1957-10-16 1960-06-07 Gay W Roach Cotton weighing machine
CN1102039A (zh) * 1993-02-03 1995-04-26 帝人株式会社 含有异碳环素作为活性成分的外用皮肤治疗剂组合物
AU669783B2 (en) * 1993-02-03 1996-06-20 Teijin Limited Dermatologic preparation composition containing prostacyclinas active ingredient
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812193B1 (fr) * 2000-07-28 2003-10-24 Oreal Utilisation d'antagoniste des recepteurs des prostaglandines ep-2 et/ou ep-4 pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
FR2812191B1 (fr) * 2000-07-28 2003-10-17 Oreal Utilisation d'agonistes du recepteur des prostaglandines e2 (ep-3) pour attenuer, diminuer ou stopper la pousse des cheveux et des poils dans des preparations cosmetiques
US20050009918A1 (en) 2003-04-02 2005-01-13 Nexmed (Holdings) Inc. Prostaglandin compositions and methods for the treatment of vasospasm
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
CA2838109C (en) * 2011-04-07 2020-06-09 Nexmed Holdings, Inc. Topical semisolid prostaglandin e1 composition for treating raynaud's disease
US10383839B2 (en) 2011-06-30 2019-08-20 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3735005A (en) * 1970-08-19 1973-05-22 Alza Corp Method for preparing a viable platelet concentrate
EP0132027A1 (en) * 1983-05-20 1985-01-23 Taisho Pharmaceutical Co. Ltd Fat emulsion containing prostaglandin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU511711B2 (en) * 1976-12-30 1980-09-04 Upjohn Company, The 6-Oxo and 5, 6-Dihalo prostaglandin analogues
US4205178A (en) * 1976-12-30 1980-05-27 The Upjohn Company 6-Keto prostaglandin E-type compounds
JPS6022710B2 (ja) * 1977-09-16 1985-06-03 小野薬品工業株式会社 プロスタグランジン類似化合物
US4707495A (en) * 1985-10-28 1987-11-17 Ortho Pharmaceutical Peptic ulcer treatment method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3735005A (en) * 1970-08-19 1973-05-22 Alza Corp Method for preparing a viable platelet concentrate
EP0132027A1 (en) * 1983-05-20 1985-01-23 Taisho Pharmaceutical Co. Ltd Fat emulsion containing prostaglandin

Also Published As

Publication number Publication date
EP0292643A1 (de) 1988-11-30
AU1518492A (en) 1992-06-25
AU1176688A (en) 1988-08-18
HUT46224A (en) 1988-10-28
DE3704825A1 (de) 1988-08-25
CA1327359C (en) 1994-03-01
ZA881053B (en) 1988-08-12
GR3005743T3 (enExample) 1993-06-07
DK77588D0 (da) 1988-02-15
JPS63246331A (ja) 1988-10-13
ATE80616T1 (de) 1992-10-15
DE3874610D1 (enExample) 1992-10-22
HU199687B (en) 1990-03-28
ES2043696T3 (es) 1994-01-01
DK173552B1 (da) 2001-02-26
EP0292643B1 (de) 1992-09-16
DK77588A (da) 1988-08-17
AU649130B2 (en) 1994-05-12

Similar Documents

Publication Publication Date Title
US5464868A (en) Prostaglandin E1 derivatives for transdermal administration and methods of treatment therewith
JP3701870B2 (ja) 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ
US8071613B2 (en) Anti-constipation composition
AU649130B2 (en) Pharmaceutical compositions for transcutaneous administration
HK1202524A1 (en) Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
AU752049B2 (en) Method and composition for treatment of erectile dysfunction
US6562868B1 (en) Method for treatment of female sexual dysfunction
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
JP6030168B2 (ja) 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ
JP5925158B2 (ja) 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ
JP6306067B2 (ja) 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ
CN105566192B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的前列腺素及相关化合物的前药
HK1137411B (en) Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
FI62067B (fi) Analogifoerfarande foer framstaellning av terapeutiskt aktiva 15-metylprostaglandinfoereningar